Literature DB >> 7689703

Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat.

P Celada1, F Artigas.   

Abstract

We have examined the local and systemic effects of clorgyline, tranylcypromine and deprenyl on extracellular serotonin (5-HT) and 5-hydroxyindoleacetic acid in the raphe nuclei and in frontal cortex of awake, freely-moving rats using microdialysis. When administered through the dialysis probe, monoamine oxidase (monoamine: oxygen oxidoreductase (deaminating), E.C. 1.4.3.4., MAO) inhibitors increased 5-HT output in a dose-dependent manner in both brain areas. The effects were more pronounced in the raphe nuclei for the three MAO inhibitors at all doses assayed. When the monoamine oxidase inhibitors were given i.p., dialysate 5-HT increased dramatically, after tranylcypromine (15 mg/kg), in raphe nuclei and frontal cortex (area under the curve (AUC) to 4 h post-treatment: 63-fold and 11-fold, respectively) whereas the effects of clorgyline (10 mg/kg) were much less pronounced (+47% increase in the AUC for raphe nuclei, P < 0.09; +18% increase in the AUC for frontal cortex, n.s.). Deprenyl (2.5 mg/kg, i.p.) induced a moderate (+22%) increase of dialysate 5-HT from the raphe nuclei but did not cause a change in dialysate 5-HT from the frontal cortex (+4%). However, clorgyline, or deprenyl, dramatically increased dialysate 5-HT in animals which had been pre-treated with the above dose of deprenyl, or clorgyline, respectively, showing that the blockade of both forms of MAO results in much larger increases of extracellular 5-HT than does the blockade of either form alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689703     DOI: 10.1007/bf00166940

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  42 in total

1.  Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors.

Authors:  P Blier; C de Montigny
Journal:  Neuroscience       Date:  1985-12       Impact factor: 3.590

2.  Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system.

Authors:  P Blier; C De Montigny; A J Azzaro
Journal:  J Pharmacol Exp Ther       Date:  1986-06       Impact factor: 4.030

3.  The monoamine oxidase inhibitors clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline and serotonin by rat brain synaptosomal preparations.

Authors:  J C Lai; T K Leung; J F Guest; L Lim; A N Davison
Journal:  Biochem Pharmacol       Date:  1980-10-15       Impact factor: 5.858

4.  In vivo evidence that 5-hydroxytryptamine (5-HT) neuronal firing and release are not necessarily correlated with 5-HT metabolism.

Authors:  F Crespi; J C Garratt; A J Sleight; C A Marsden
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

5.  Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.

Authors:  A R Green; M B Youdim
Journal:  Br J Pharmacol       Date:  1975-11       Impact factor: 8.739

6.  Serotonin metabolism by monoamine oxidase in rat primary astrocyte cultures.

Authors:  L W Fitzgerald; L Kaplinsky; H K Kimelberg
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

7.  Serotonin and 5-hydroxyindoleacetic acid in plasma. Potential use as peripheral measures of MAO-A activity.

Authors:  P Celada; M J Sarrias; F Artigas
Journal:  J Neural Transm Suppl       Date:  1990

8.  Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study.

Authors:  N Bel; F Artigas
Journal:  Eur J Pharmacol       Date:  1992-12-08       Impact factor: 4.432

9.  Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists.

Authors:  J S Sprouse; G K Aghajanian
Journal:  Synapse       Date:  1987       Impact factor: 2.562

10.  Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex.

Authors:  R Invernizzi; S Belli; R Samanin
Journal:  Brain Res       Date:  1992-07-03       Impact factor: 3.252

View more
  6 in total

Review 1.  Context-dependent modulation of auditory processing by serotonin.

Authors:  L M Hurley; I C Hall
Journal:  Hear Res       Date:  2010-12-25       Impact factor: 3.208

2.  Serotonin in the inferior colliculus fluctuates with behavioral state and environmental stimuli.

Authors:  Ian C Hall; George V Rebec; Laura M Hurley
Journal:  J Exp Biol       Date:  2010-04       Impact factor: 3.312

Review 3.  Imaging the serotonin transporter during major depressive disorder and antidepressant treatment.

Authors:  Jeffrey H Meyer
Journal:  J Psychiatry Neurosci       Date:  2007-03       Impact factor: 6.186

4.  A microdialysis study of glycinamide, glycine and other amino acid neurotransmitters in rat frontal cortex and hippocampus after the administration of milacemide, a glycine pro-drug.

Authors:  M H Doheny; S Nagaki; P N Patsalos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

5.  The pharmacology of the neurochemical transmission in the midbrain raphe nuclei of the rat.

Authors:  L G Harsing
Journal:  Curr Neuropharmacol       Date:  2006-10       Impact factor: 7.363

6.  Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography.

Authors:  Marie Spies; Gregory M James; Neydher Berroterán-Infante; Harald Ibeschitz; Georg S Kranz; Jakob Unterholzner; Mathis Godbersen; Gregor Gryglewski; Marius Hienert; Johannes Jungwirth; Verena Pichler; Birgit Reiter; Leo Silberbauer; Dietmar Winkler; Markus Mitterhauser; Thomas Stimpfl; Marcus Hacker; Siegfried Kasper; Rupert Lanzenberger
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.